ropivacaine
Commercial- Indications
- Pain
Company intelligence / Profile preview
Navinta has a portfolio of at least seventeen approved drugs in the U.S., with expertise in complex generics and novel formulations. The company holds over twenty process/product patents and maintains an active pipeline focused on oral dosage forms, injectables, sprays, and APIs. Their regulatory strategy includes both ANDA filings for generics and NDA submissions for differentiated products. They have a DEA registered facility for controlled substances manufacturing.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Navinta LLC.